NextCure Updates ADC Pipeline Progress and Cash Runway

An announcement from NextCure ( (NXTC) ) is now available.

On January 23, 2026, NextCure reported program and financial updates, highlighting progress in its two antibody-drug conjugate candidates and outlining its cash position. The company plans to present Phase 1 dose-escalation data for SIM0505, a cadherin-6–targeting ADC focused on advanced solid tumors and particularly platinum-resistant ovarian and other gynecological cancers, in the second quarter of 2026, and is adding clinical sites and increasing drug supply ahead of dose optimization. For LNCB74, a B7-H4–targeting ADC, dosing has begun in higher-dose cohorts in its Phase 1 study prioritizing patients with high B7-H4 expression in breast and gynecological cancers and now including adenoid cystic carcinoma type 1, while proof-of-concept data have been delayed in favor of a broader enrollment window, with a trial progress update now expected in the second half of 2026. Financially, NextCure reported preliminary, unaudited cash, cash equivalents and marketable securities of approximately $41.8 million as of December 31, 2025, which it expects will fund operations into the first half of 2027, underscoring both the runway to advance its oncology pipeline and the ongoing execution risk typical of early-stage biotech development.

The most recent analyst rating on (NXTC) stock is a Hold with a $13.50 price target. To see the full list of analyst forecasts on NextCure stock, see the NXTC Stock Forecast page.

Spark’s Take on NXTC Stock

According to Spark, TipRanks’ AI Analyst, NXTC is a Neutral.

The score is held down primarily by weak financial performance (no revenue, continued losses, and heavy cash burn with elevated funding/dilution risk). This is partly offset by strong technical uptrend and supportive recent financing actions that extend runway, while valuation remains constrained by unprofitability and lack of dividend support.

To see Spark’s full report on NXTC stock, click here.

More about NextCure

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapies, including antibody-drug conjugates, to treat cancer patients who do not respond to or progress on existing treatments. Leveraging its expertise in biological pathways, biomarkers and tumor microenvironment interactions, the company is advancing programs such as SIM0505 and LNCB74 for the potential treatment of advanced solid tumors through global rights and co-development partnerships.

Average Trading Volume: 45,912

Technical Sentiment Signal: Buy

Current Market Cap: $46.52M

See more insights into NXTC stock on TipRanks’ Stock Analysis page.